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Cardiac tamponade is a rare extraintestinal manifestation of ulcerative colitis. We present a case report of tamponade occurring
four years after curative proctocolectomy and in the absence of any medical therapy for ulcerative colitis. Options for medical
management of this condition are also discussed.
1.Introduction
Cardiac tamponade is a rare extraintestinal manifestation of
ulcerative colitis (UC) with only nine reported cases in the
literature. However, association of UC and tamponade has
been called into question given the diﬃculty of complete
exclusion of other causes, as well as concomitant use
of sulphasalazine/5-aminosalicylic acid (5-ASA) that can
adversely aﬀect the pericardium [1].
We present a case which broadens the understanding
of UC-associated pericarditis and tamponade by under-
lining that this condition may develop in the absence of
concomitant 5-ASAs or sulphasalazine treatment and even
several years after curative total colectomy. In addition,
we emphasize that quick tapering of steroids may lead to
recurrence of the disease, and colchicine may be beneﬁcial
in maintenance of remission.
2.CaseReport
A 35-year-old male presented in May 2008 with low-grade
fever and left upper quadrant abdominal pain. His past
medical history comprised of UC for seven years, for which
he was on no medication after a curative proctocolectomy
with end-ileostomy were carried out in 2004. He also had
postoperativeneurogenicbladderandrecurrenturinarytract
infections (UTIs), asthma, and three-year history of self-
limiting pleuritic chest pains. His medications included
budesonide/formoterol inhaler, pantoprazole, vitamin D,
and calcium.
Physical examination including vital signs and jugular
venous pressure was within normal limits. Following a chest
X-ray, CT scan of abdomen, and ECG that were all reported
to be normal, the patient was admitted for observation and
treatment with ciproﬂoxacin for UTI (Klebsiella pneumo-
niae and Escherichia coli).
Onthefourthdayofadmission,hedevelopedprogressive
left-sided pleuritic chest pain radiating to his back and
shortness of breath. Physical examination revealed normal
temperature,tachypnea,tachycardia,andhypotension.Jugu-
lar veins were engorged up to the angle of the jaw. No
pericardialrubormurmurwasappreciated.Lungswereclear
to auscultation and abdomen was soft and nontender. No
oral lesions, rash, arthritis, or peripheral edema were noted.
Arterial blood gas showed PaO2 of 48, PCO2 of
41mmHg, and saturation of 84% on room air. Electro-
cardiogram showed ST elevation and PR depressions in
all leads. CT angiography of chest did not show any
pulmonary embolism but revealed moderate-size pericardial
eﬀusion and bilateral pleural eﬀusions (Figure 1). Urgent
transthoracic echocardiogram was carried out and showed
cardiac tamponade. Subsequently, an urgent pericardial tap2 Case Reports in Medicine
Table 1: Relevant blood and serologic ﬁndings.
Data Laboratory results Normal range
Blood and serologic ﬁndings
Hemoglobin, g/L 129 135–175
WBC, 109/L 7.1 4–11
Platelets, 109/L 163 140–450
Total protein, g/L 62 64–84
Creatinine, µmol/L 70 45–125
Urea, mmol/L 2.5 2.5–8.0
Creatinine kinase, unit/L 215 <250
Troponin, µg/L <0.10 <0.15
ESR, mm/hour 77 0–15
CRP, mg/L 35.6 <8.0
Lactate dehydrogenase, U/L 135 100–225
TSH, mU/L 0.73 0.2–4.0
ANA Negative Negative
Anti-ds DNA, % 20 – 1 5
Rheumatoid factor, kU/L <9 <20
C3, g/L 1.76 0.8–2.0
C4, g/L 0.27 0.18–0.36
HIV serology Negative Negative
Table 2: Laboratory data on pericardial ﬂuid.
Pericardial ﬂuid analysis
WBC, 106/L 2000
Neutrophils, % 74
Lymphocytes, % 8
Monocytes, % 16
Eosinophils,% 2
Total protein, g/L 43
Lactate dehydrogenase, U/L 581
Glucose, mmol/L 4.3
Viral/bacterial/AFB culture Negative
S h e l lv i a lc u l t u r ef o rC M V N e g a t i v e
Enterovirus RNA Negative
Cytology Negative
was performed and a total of 600cc of clear ﬂuid was drained
over the next 3 days (Tables 1 and 2).
Patient was started on prednisone 70mg daily and
colchicine 0.6mg twice daily, and pericardial drain was
removed four days later. His symptoms completely resolved
over the next 48 hours and he was discharged with a
tapering schedule to reduce the dose of prednisone to 20mg
in two weeks. After two weeks, patient represented with
pleuritic chest pain and recurrent ECG changes suggestive
of pericarditis. Echocardiogram and chest X-ray did not
reveal pericardial or pleural eﬀusion. Prednisone dosage was
increased to 50mg daily and was tapered over a 3-month
period while colchicine was continued at the same dose.
As of twelve months of follow-up he has not experienced
Figure 1: CT scan showing pericardial (dashed arrow) and bilateral
pleural eﬀusion (solid arrows).
any clinical or ECG ﬁnding suggestive of recurrent pleuro-
pericardial involvement. Of note that throughout the course
ofthediseasethepatientdidnothaveanysymptomsofactive
inﬂammatory bowel disease.
3. Discussion
Pericarditis is a known but rare complication of UC [2].
Recurrent and chronic pericarditis has also been reported
[1]. With a much lower incidence, inﬂammatory bowel
disease has been associated with pericardial tamponade (1
and 10 cases in Crohn’s disease and UC, resp.) [1, 3].
As UC-associated pericardial eﬀusion is a diagnosis of
exclusion, previous case reports, particularly older reports,
are scrutinized for lack of laboratory and microbiologic
evidence to rule out secondary causes of pericardial eﬀusion.
In this case, extensive viral, bacterial, mycobacterial, and
fungal studies were performed with negative results. In addi-
tion,connectivetissuediseases,uremia,hypothyroidism,and
malignant causes were excluded (Tables 1 and 2).
5-ASA and sulphasalazine have been associated with
myopericardial involvement [4]; moreover, sulphasalazine
can cause drug-induced lupus with a range of manifestations
including pericardial involvement [5]. This patient has not
received any of these compounds for more than four years
making these drugs an unlikely cause for his condition.
Patient had not been started on any new medications
except ciproﬂoxacin for UTI which to our knowledge is not
associated with pericardial involvement.
Postoperative UC-associated tamponade has been
reported in three cases following subtotal colectomy [3, 6, 7].
Occurrence of tamponade four years after total colectomy
signiﬁes that extraintestinal manifestation of UC can still
occur despite inactive UC.
Lack of signiﬁcant pericardial ﬂuid on the CT scan four
days prior to tamponade provided us with an opportunity to
elaborate the acuteness of UC-induced tamponade.Case Reports in Medicine 3
Recurrence of pericardial disease after rapid tapering of
the prednisone dose has been reported previously in UC
patients[1].Similarphenomenonoccurredinthiscase;how-
ever, slow tapering of prednisone over three months similar
to standard steroid therapy for UC ﬂare-ups prevented the
recurrence for the second time.
Despite the promising results of the COPE trial [8]o n
beneﬁcial eﬀects of colchicine in reduction of pericarditis
recurrence, eﬀect of colchicine on UC-associated pericardial
disease has not been evaluated. Given the deleterious eﬀects
of NSAIDs on ulcerative colitis [9], colchicine was started in
this patient. Lack of further symptoms after slow tapering
and discontinuation of steroids might suggest a positive
role for colchicine in maintaining the prednisone-induced
remission in UC-induced pericarditis.
In conclusion, cardiac tamponade should be considered
as a potential life-threatening extraintestinal manifestation
of UC and be treated accordingly. It should be noted that
currently a causal relationship between IBD and cardiac
tamponade is not established.
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